<SEC-DOCUMENT>0001129928-12-000070.txt : 20121109
<SEC-HEADER>0001129928-12-000070.hdr.sgml : 20121109
<ACCEPTANCE-DATETIME>20121109114724
ACCESSION NUMBER:		0001129928-12-000070
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20121109
FILED AS OF DATE:		20121109
DATE AS OF CHANGE:		20121109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		121192385

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<DESCRIPTION>6K FORM
<TEXT>
<html>
<head>
    <title>form6-k.htm</title>
    <!--Licensed to: Oncolytics Biotech Inc-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">Form 6-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Report of Foreign Private Issuer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Rule&#160;13a-16 or 15d-16</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">of the Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the month of&#160;November 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Commission File Number 000-31062</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">__________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Translation of registrant&#8217;s name into English)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Suite&#160;210, 1167 Kensington Crescent NW</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Calgary, Alberta, Canada T2N 1X7</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">__________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;(Address of principal executive offices)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or Form&#160;40-F.</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form&#160;20-F&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">&#254;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form&#160;40-F&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if submitted solely to provide an attached annual report to security holders.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form&#160;6-K submission or other Commission filing on EDGAR.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Yes&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">No&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">&#254;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule&#160;12g3-2(b):&#160;&#160;&#160;82&#160;-&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXHIBIT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NUMBER</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="69%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DESCRIPTION</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="69%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="69%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">News Release Dated November 9, 2012: Oncolytics Biotech&#174; Inc. Collaborators Present Positive REOLYSIN&#174; Trial Results and Research at EORTC-NCI-AACR Symposium</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="4" valign="top" width="39%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Registrant)</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date:&#160;&#160;November 9, 2012</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="36%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">/s/&#160;&#160;Doug Ball</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Doug Ball</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1 CHARTER
<SEQUENCE>2
<FILENAME>ex99.htm
<DESCRIPTION>RELEASE
<TEXT>
<html>
<head>
    <title>ex99.htm</title>
    <!--Licensed to: Oncolytics Biotech Inc-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><img src="onclogo.jpg" alt=""><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">210, 1167 Kensington Cr. N.W.</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Calgary, Alberta</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Canada T2N 1X7</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR IMMEDIATE RELEASE</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Oncolytics Biotech<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> Inc. Collaborators Present Positive REOLYSIN<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> Trial Results and Research at EORTC-NCI-AACR Symposium</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">CALGARY, AB, November 9, 2012 ---</font> Oncolytics Biotech Inc.&#160;("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced three poster presentations covering expanded results from: a Phase II clinical trial using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with <font style="FONT-STYLE: italic; DISPLAY: inline">Kras</font> or EGFR-activated tumours (REO 016), a Phase II clinical trial using intravenous administration of REOLYSIN<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#160;</font>in combination with gemcitabine (Gemzar<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font>) in patients with advanced pancreatic cancer (REO 017), as well as preclinical research in Ras-activated pancreatic cancer. The presentations are being made at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held in Dublin, Ireland from November 6<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> through 9<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font>, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;We continue to expand our library of positive clinical data in a variety of indications like lung and pancreatic cancers,&#8221; said Dr. Brad Thompson, President and CEO of Oncolytics. &#8220;Positive results from these earlier studies have further validated our decisions to advance both these indications into randomized Phase II testing.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The poster presentation titled &#8220;Phase II Trial of Oncolytic Reovirus in Combination with Chemotherapy in NSCLC Pts with <font style="FONT-STYLE: italic; DISPLAY: inline">Kras</font> Activated Tumors&#8221; covers the latest results from the REO 016 study. Thirty-three of a planned 36 patients had received Reovirus (REOLYSIN) (3 x 10<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">10</font> TCID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: sub">50</font>) intravenously daily on days one to five, in combination with carboplatin and paclitaxel.&#160;&#160;Molecular tumor demographics included: 16 <font style="FONT-STYLE: italic; DISPLAY: inline">Kras</font>, three EGFR, four BRAF mutations, and 10 EGFR amplified only. Response evaluation to date among 30 evaluable patients showed 27 patients had stable disease or better for a 90% clinical benefit rate (nine partial response (PR) (30%) and 18 stable disease (SD) (60%)). Three patients had progressive disease (PD) as their best response.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The poster presentation titled &#8220;A study of REOLYSIN in Combination with Gemcitabine in Patients with Advanced Pancreatic Adenocarcinoma&#8221; covers updated results from the REO 017 study. The trial is a 33-patient study using a one sample, two-stage design. In the first stage, 17 patients were to be enrolled, and best response noted.&#160;&#160;&#160;If three or more responses were observed (defined as complete response (CR), PR or SD for 12 weeks or more) among the 17 patients, the study would enroll an additional 16 patients for a total of 33 evaluable patients.&#160; As previously disclosed, this initial endpoint was met after six evaluable patients were enrolled and the study continued to enroll the total of 33 patients. The treatment was well tolerated. Response evaluation to date among 25 evaluable patients showed 20 patients had stable disease or better (one PR, one unconfirmed PR, 6 SD at six weeks, and 12 SD at 12 or more weeks). Five patients had PD as their best response.&#160;&#160;A number of patients remain on study with some too early in their treatments to evaluate.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The poster presentation titled &#8220;Reovirus Therapy Induces Endoplasmic Reticular (ER) Stress and Apoptosis in RAS-Activated Pancreatic Cancer&#8221; discusses findings from preclinical research conducted using REOLYSIN. The researchers demonstrated that cells with activated RAS are under intrinsically higher levels of ER stress and that reovirus infection leads to enhanced ER stress and apoptosis in mutant RAS pancreatic cancer cells. Further induction of ER stress with bortezomib increases the efficacy of REOLYSIN against pancreatic cancer cells.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">&#160;</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.&#160;&#160;Oncolytics' clinical program includes a variety of human trials using REOLYSIN<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font>, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.oncolyticsbiotech.com</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.S. Phase II clinical trial investigating REOLYSIN in combination with paclitaxel and carboplatin patients with non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumours, the</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">U.S. Phase II clinical trial investigating REOLYSIN in combination with Gemcitabine in patients with advanced or metastatic pancreatic cancer, the preclinical work conducted in RAS-activated pancreatic cancers, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR FURTHER INFORMATION PLEASE CONTACT:</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="27%" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: #ffffff 0.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Equicom Group</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nick Hurst</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">300 5<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Ave. SW, 10<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Calgary, Alberta&#160;&#160;T2P 3C4</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tel: 403.218.2835</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fax: 403.218.2830</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">nhurst@equicomgroup.com</font></font></div>
</td>
<td valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: #ffffff 0.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dian Griesel Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tom Caden</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">398 West Broadway, 2<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">nd</font> Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">New York, NY&#160;&#160;10012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tel:&#160;&#160;212.825.3210</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">tcaden@dgicomm.com</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-30-</font></div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>onclogo.jpg
<DESCRIPTION>LOGO
<TEXT>
begin 644 onclogo.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X0E(17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````0````<@$R``(````4````@H=I``0````!````E@```+8```$L````
M`0```2P````!4&%I;G0N3D54('8U+C`P`#(P,#@Z,#4Z,C(@,34Z,CDZ,S@`
M``*@`@`$`````0```\"@`P`$`````0```.$`````````!@$#``,````!``8`
M``$:``4````!```!!`$;``4````!```!#`$H``,````!``(```(!``0````!
M```!%`("``0````!```(+`````````!(`````0```$@````!_]C_X``02D9)
M1@`!`@$`2`!(``#_[0`,061O8F5?0TT``?_N``Y!9&]B90!D@`````'_VP"$
M``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,
M#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(
M`"8`H`,!(@`"$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````````#``$"
M!`4&!P@)"@L!``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($
M`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#
M!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$
MU.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&
M!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S
M-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6U
MQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/55C]2^
ML3,?,_9O3\=_4^I@!S\>DAK:VGZ+LS)?^BQMWYG^%_X-%^L?4KNF])MOQFA^
M786T8C#WNN<*:/\`->_U%/HG1Z.D8+<:LFVYY-F5DNU?=<[W77VN^DYSW)I)
M)H:=RIH[_KT[WBKI=0.OI.?>YP_DNM:QK/\`P-*GZRW8V37A]?PSTRVXAE&2
M'BW%L<>*VY(#/1M?^95D,8MY`S<+%S\6W#S*VW8][=ME;N"#_K[7)<)&Q/U4
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M[/HUTX=3_.R+K?\`HUVUK*HQ.HGK?7.H=),9^+E,!Q["6U9-+J:G.Q7S[:K=
M_OQLK_!6?SGZ&Q=!]7^E6=,P7-R;!=G95CLG.N:(#KK/I[/^"K;MJJ_X-B:K
MK+[,_P"QG%>T>M91ZG,>FSU6W/9M]M-WT&6?03*T%Z:D_P",EH?5&]F3D]:R
M:V65-NS`[T[FEEC3Z-#;*[*W?1?7:U]:I=-_98R,P?6P5?M0WV;'9X'H^A/Z
MN.FNR?U;[/L^DVG]-ZG])]ZZG)R319C,%;K/M-OI%S>&#T[;O4?_`"/T/I_]
M<4<_+=B8_K-J=<2]C(;PT/<&>K:[W;**MWJ76;?T=:/#IO\`+X:*<SJ0>[ZJ
MY#?JN&L=Z3AB#'`9^=^E^S_1VV?SOI?\(L[_`+!3TN"RAEVSZ&V.H"R/W?\`
ME'[=ZG_7O4718.<[+?>PU%@H>&BUIW56`M;9NHMAGJ;-WIV^S^=3?:\G]I?8
M_0'I>GZOK[C$3LV;?3V^K_(]3Z"1`-'3]W93S^8WJCO\7%S>J!YSSAN%H?K9
MW]/U-O\`A?2V>I_PBV>F=9Z3>S'Q*,RFS(-;0*FO!<2UNY_M^E[6M1^I=0=@
MMH(I-WKV^D2#`8-EEWJ6.AWM_0^G_7L5JI_J5L?I[FAVAD:C\UVB(%'0[`#5
M3S'7,;)Z+E5Y?1+1C.ZSD,Q,FES/4J;==(KZI75+?3R*MOZ?_`Y?^&_2+8P.
MA=.PL!^#Z8R*[B7Y3\B+'WV.ULNRG/\`YU[W?^HT3IW479K0\UBC<W=Z+W'U
MF:QLR*-GZ&S]_P#2V(N5E.Q[,9C:7W?:+342R/8!7;?ZC]WMV?H?3_ZXD`-3
MT*GG>G=%Z/9]9NLX]F!COHJKQ#56ZEA8TO;=ZOI,<WTV[]OZ38K7UI'ZWT"!
MQU*O@<?H[_!;&!E.S,87NJ?02^QGIV:.'IO?3+OZ_I[U80$1PT.NO_=*>;^L
MF_\`:N`>HA[OJ^&O^TA@<:_7D>A^T&U>[['_`%_U;U?Z0KW2S]6/M3OV.,3[
M0:_>[$#/H`C1[Z!M^G^8KV/E&[(RJ36Y@QGM8'NX?NKKNWL_J^KZ?]A4^H]:
MLP+KV?8[KZZ:&W"VL%P+WFYM>/M:USO=Z'\[[_2]6OUO39[TM`>+]BGGLRGH
M[,_.O;G]-R;;+7.MHZO6'VL</8ZC&O=978S$;M_0U?9K_P#@UT'U9O%_1Z7M
MP?V:P%[68^H;M#C%M(<VJST;OYROU*JE=SLHX>*_(%3[RR/T=8EWN<&;O^+K
MW>I;_P`$I8MYOK+SZ9@Q^B?ZC?\`/V5I"-2W_!3_`/_1]56;U[]@_8'?M[T/
ML<_]J(C=_P`%^?ZO_%?I%\SI(2V.WUV4^Z,H^J3JM^-D]79A]JZAU'T8_D_H
MG>S^VMKZL_\`-3T[/^;_`*.^?T\3Z_\`Z$?:/UO_`+=7SBDHX[CY?I_W*?M?
MJI)?*J2E0_522^54DE/U4DOE5))3]5)+Y5224_522^54DE/U4DOE5))3]5)+
MY5224_522^54DE/_V?_B#%A)0T-?4%)/1DE,10`!`0``#$A,:6YO`A```&UN
M=')21T(@6%E:(`?.``(`"0`&`#$``&%C<W!-4T94`````$E%0R!S4D="````
M``````````````#VU@`!`````-,M2%`@(```````````````````````````
M````````````````````````````````````$6-P<G0```%0````,V1E<V,`
M``&$````;'=T<'0```'P````%&)K<'0```($````%')865H```(8````%&=8
M65H```(L````%&)865H```)`````%&1M;F0```)4````<&1M9&0```+$````
MB'9U960```-,````AG9I97<```/4````)&QU;6D```/X````%&UE87,```0,
M````)'1E8V@```0P````#')44D,```0\```(#&=44D,```0\```(#&)44D,`
M``0\```(#'1E>'0`````0V]P>7)I9VAT("AC*2`Q.3DX($AE=VQE='0M4&%C
M:V%R9"!#;VUP86YY``!D97-C`````````!)S4D="($E%0S8Q.38V+3(N,0``
M````````````$G-21T(@245#-C$Y-C8M,BXQ````````````````````````
M``````````````````````````````````````````!865H@````````\U$`
M`0````$6S%A96B``````````````````````6%E:(````````&^B```X]0``
M`Y!865H@````````8ID``+>%```8VEA96B`````````DH```#X0``+;/9&5S
M8P`````````6245#(&AT='`Z+R]W=W<N:65C+F-H```````````````6245#
M(&AT='`Z+R]W=W<N:65C+F-H````````````````````````````````````
M`````````````````````````&1E<V,`````````+DE%0R`V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@``````````````+DE%
M0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@``
M``````````````````````````!D97-C`````````"Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ```````````````L4F5F
M97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````
M````````````````````````````=FEE=P``````$Z3^`!1?+@`0SQ0``^W,
M``03"P`#7)X````!6%E:(```````3`E6`%````!7'^=M96%S``````````$`
M```````````````````````"CP````)S:6<@`````$-25"!C=7)V````````
M!``````%``H`#P`4`!D`'@`C`"@`+0`R`#<`.P!``$4`2@!/`%0`60!>`&,`
M:`!M`'(`=P!\`($`A@"+`)``E0":`)\`I`"I`*X`L@"W`+P`P0#&`,L`T`#5
M`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K`3(!.`$^`44!3`%2`5D!
M8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!N0'!`<D!T0'9`>$!Z0'R`?H"`P(,
M`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8`J("K`*V`L$"RP+5`N`"
MZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#E@.B`ZX#N@/'`],#X`/L
M`_D$!@03!"`$+00[!$@$501C!'$$?@2,!)H$J`2V!,0$TP3A!/`$_@4-!1P%
M*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2`99!FH&>P:,
M!IT&KP;`!M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^4'^`@+"!\(
M,@A&"%H(;@B"")8(J@B^"-((YPC["1`))0DZ"4\)9`EY"8\)I`FZ"<\)Y0G[
M"A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+@`N8"[`+R`OA"_D,
M$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-C@VI#<,-W@WX#A,.+@Y)
M#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L$`D0)A!#$&$0?A";$+D0
MUQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02HQ+#$N,3`Q,C$T,38Q.#
M$Z03Q1/E%`84)Q1)%&H4BQ2M%,X4\!42%3055A5X%9L5O17@%@,6)A9)%FP6
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MUS@4.%`XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB
M/6$]H3W@/B`^8#Z@/N`_(3]A/Z(_XD`C0&1`ID#G02E!:D&L0>Y",$)R0K5"
M]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C7
M21U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/
M24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"
M5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<
MUETG77A=R5X:7FQ>O5\/7V%?LV`%8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K
M9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]K
MIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9PX'$Z<95Q\')+<J9S`7-=
M<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[
MPGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!:X'-@C""DH+T@U>#NH0=
MA("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-
M,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.339.VE""4BI3TE5^5R98T
MEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?
M^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFI
MJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP`+!UL.JQ8+'6LDNRPK,XLZZT
M);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$
MOO^_>K_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)
MN<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N-`YT+K1/-&^TC_2P=-$T\;42=3+
MU4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@
MO>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&
M[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY
M./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW____;`$,``0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`'`!X`,!(@`"$0$#
M$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_Q`"U$``"`0,#
M`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S
M8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H
M:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#
M`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!
M`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q
M%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X
M>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(
MR<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$``A$#$0`_`/[^
M****`"BBB@`HKAOB)\2?`_PG\+:GXX^(_BK0/!?A#18&N-4\0^)=4M-(TNS0
M<*KW5[+%&\\[$0VMM$9+FZN'CM[>*2615K\"?VE_^#@+X7^%+F_\-_LS?#F\
M^)^H6YDMT\>>-YKKPMX*,X8*+G2_#\2?\)5XAL\A0HO7\)/.'#VCSHJL_@YO
MQ)D^104\SQE*AS1YH44^?$3CIK&EHW:^OJC6E1J5I<M.+EW?1?\`#G]%]%?P
M^ZK_`,%._P#@J7^TKJMSI_PSU_QE"D[L/^$6^`'PM2=K42D%(HM2L-'\1^+H
MHE#1HLD^O/<;AM\QY'I\7@#_`(+>:^HU(7'[>48G`<*_C_XE^'R%;)'_`!+I
M?$FEF'Z?9(F'\2C*Y^1_XB7AZMI8#AW/\?2_Y^TL+:'2UG[U[W?;;[NCZE)?
M%5I+M[U^WY7^[[C^W^BOX<[KXA_\%I?@2IU;6=0_;/TZRLQYL^H^+=(\9_$+
M0H8DSN:ZG\2:?XHT=H@$9I#<RDA2690L1(]P^"__``7Q_:F\!WUOI7QP\$^"
M_C!H]N_DZC/'8'X=>.$8,L4Q%YI4$_AIS#B1A:3>$X9Y70Q27<:%YE=#Q.RA
M58TLSR_-<H;WJ8O#/V4;6O?E_>2W7\.E-*_O-:-OZA4E_#J4IVW]ZUMO5/K]
MQ_8Y17YS_LF?\%0?V6/VNGL]`\(>*)?!/Q)N44'X8_$#[)HGB.[G"$S)X=NQ
M<S:+XKC0I(PCT34)]3CM@+B^TRQ7<B_HQ7WV!S'!9GAX8K`8FEBL/-7C5I2Y
MHOOV:MYI''.$Z<G"<7&2W3_SZA1117:2%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%?$W[;7[<GPG_8C^&@\9
M^/IO[9\5:VEU:?#[X<Z7=11Z_P",M7@1`^QG60:9H&FF:&;6]?GAEMK&%H[>
MWBOM6NM/TR\]M_:'^//@?]FCX0>-OC1\1;O[-X7\%Z//?RP0O&-0UC5)&2VT
M;P[I,4A59M5U[4Y[;3;%&98DFG$UR\5K'--'_%5X0\,_M#_\%?OVR[^_U6_G
ML8+^9=0\1:SLN+OPO\&_A597VVRTC2H&9`T\<4QT[1[`-#<>)?$5S<:SJCQ^
M?K>I0_"\7\45\J6%RS*:/UO/,SE[+"4(^][!/EM7K1MI;F]R+:4K2?,K'7A:
M$:SG.J[4J4>>?GV6^BON]?3<DUCQ!^W'_P`%?OCE_9UA#>:WI^FW9N;70;.X
MN=$^#?P>T.ZG>".ZU"X<S6L%SY#2(^HW0U/Q;XA>&>WL5N@L-A!_0/\`LF_\
M$0?V9?@G8Z9X@^-4(_:!^(T*Q3W(\002V?PWTR]`5GATOP<DJC6X8V#QM<^+
MIM2AOE`NAH^G2L(X_P!.OV</V;?A3^RS\,-&^%'PBT"#1?#^F11R7]\\<3ZY
MXGUHQ(E[XD\3:BD<;ZGK.HLBM-,RI!;PK#8:=;V>G6MK:0>^5RY#P#@\,WF6
M?MYSG=>;K5JN*;JT*,I+6G"C)NE5L]'.I![>ZH]:JXZ4TZ>'Y:5%6Y>6-F[V
MW[6MWO=LY_PSX5\-^#=)M]!\*>']$\,Z):(L=IH_A[2K'1M,M8U4(L=O8Z=!
M;6L**JJH6.)<`=3VZ"BBOT&G"-."A",816T8148KT2V.(*^5OCS^Q3^S%^TO
MI]S:?&#X1>$/$NH7$;I'XJMM.30O&MBSY(FL?%VB&QU^-HW/FK!-?3V4S@+=
M6MQ#NB;ZIHK+$87#XN#I8FA1KTY?%"M2IU8O;I.,NW3?J4I2C\+:]#^//]MC
M_@B1\5?@1%??%3]EK6-?^*_@?1Y#JUQX1=1%\6?",5JYNUO](?25M8?&-OIY
MACG,VD0:?XD@$:-#HFH"U:['K'_!-?\`X+,ZYX9U/0_@-^V+KD^J^'Y[BWT'
MPE\:-89AK7ABZ686MOH_Q,ED7SM3T@RN+5/%LX&JZ+(JGQ(UW8"[U?2OZM*_
MG-_X*[_\$L=)\=Z'XD_:D_9V\/1V/Q'TFVOO$'Q6\`Z+:%;?Q_I=M$9M1\6Z
M!I]N-D/C/354WNKV-M"R^++);RY2"7Q./^)Y^89QPOC>&:\L_P"$9S@H:X_)
M6G/#8G#Z<[ITKI7BFW:VB>C/0HXF.(4</BO>3TA53M.&U[.S7O>[>_9>9_11
M97EO?VT-W:RQ7%M<PQ7%M<6\JSV]Q;SKYD$\$R9CFBFB*2QRQL\;QNKH[*0Q
MM5_,7_P1%_X*&7NHS6/[&7QBUJ2]O(K29_@3XEU:Z9[B6TTZVDN+WX97MY,3
M).]E903:AX.>9G=+"VO]`1UBM-!LJ_ITK[OA[/L+Q%EE',L+[JG^[KT7*\\/
MB8V]I1EHK\MU:5E>^R:.*M2E1J2IRZ:Q?\T'\,K=+_/U"BBBO<,@HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***I:CJ%KI=
ME=ZA>S);V=E:W-Y=3R':D-O:0O//*YP<)'$CN[9X`X!S0W9-]M0/Y)_^"]O[
M4][XV^+?A/\`92\+W\TGASX806'BWQW:VDCE=5^(?B6R$F@Z7<1Q_P#'P/#O
MA/4+:YMPF[=?>+;B(J)].C9/W$_X)A?L<Z?^R#^S-X<T34]/AB^*WQ"MM/\`
M''Q7U%XH_M::WJ%FLVF^$_-P7^P^"]/G&D1PAV@?5?[8U&$*FH[%_E__`&,-
M%N_VY/\`@J?HOC3Q5`VHZ/K_`,7?&/QW\307>^XMXM#\+WNJ>*]#T:X1PX;3
MOMT/ACPPELP$:6,L=LNQ%(D_NAK\IX*H1S_.,[XOQ'ON>+J8#*[_`/+G#46U
M*I&+_AU'>*C)7<??5WT]#%2]E2I8:*M[O/571N7+RKY6EHWL]D%%%%?JQYX4
M444`%%%%`!364."K`$$$$,`00>H(/4'C([XIU%`'\1__``5;_9AU/]B7]KW0
M/B]\(?M'A3PA\2-77XI_#J^TB$6<'@_XA^']5M=2\3:#IJPXCMHM.UC[!XCT
MJU&VTATS6TTB&!K339XU_K7_`&1/V@-)_:@_9W^%WQOTM8+>7QGX:M9M?TVW
M<M%H_BW3))='\7:.@8M(L6G^([#4H+1I?GN-/%I>8*7",WQ-_P`%K?@E:?%O
M]AKQKXBBM%G\0_!;6-%^)^BS+&#<)96=P-`\60"4(9$M#X6US4]2G1'0/=:3
M83,<V\>/B_\`X-X/B_/JOPR^//P/O[MI%\%>*O#?Q"\/0R.28[#QOIMWHNNV
MD'41V]E?>$=.O9%!V&?7))`/,DD4?D^5TUPWQYB<HA:&6<0X=XS#T(NU.GBH
M/VD7!7?VZ5>EO&]E+O$[Y_[1@X5I_P`6BE2YMW9)*]GWT\M-.I_2%117,>*?
M&/A+P59P:CXQ\3^'O"FG7%P+2#4/$FMZ;H5E+=LC2):Q76J7-M!)<R)'(Z0(
MYD9(Y'`VHU?JTYQA%RG)1BMY-V2^9P'3T5QWA;XA>!O'(O?^$,\9^$O%G]FF
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M7-M"2<'@/G(X[X\0_P"&QOV3OM?V/_AI+X&"YW;/*_X6KX)W^9_SS`_M?&[/
M;(KFJXS"49<M;$X>E+;EJUJ=-Z6O;GE%NUU>R\G9L:C-[1;^3[K]+_\`#7/I
MBBN4\*>-_!OC:T;4/!OBKPWXJL01F\\-Z]I>NVP],SZ7<W4(X(Q\^><'MGJZ
MVA4A4BITY1G![2BU)/OJNP@HHS7(^+/'?@OP-9+J/C3Q7X:\)Z><G[;XEU[2
M]!M>.N)]3N;6)N,X`;)Q^1.I"G%SJ2C"$=Y2=DO4#KJ*^95_;)_9,>X^RK^T
MI\##<%B@C'Q4\%`^8,?(/^)O@MSST`KW#PMXV\'>-K#^U/!WBCPYXJTXGB^\
M-ZYIFN6A]/\`2=,NKJ'/."-^0<\>N%+'8.O+DHXK#U9/[-*M3J/INH2E9]D]
M[.P^6:7O1:^3[+]7_3.JHHS_`(T5U""BN)\3_$?P!X(EM+?QGXW\'>$)[^.6
M:PA\3^)]%T"6]B@9$GDM(]6O+1[E(7D1)FA5UB:1%<JS`5T>CZQIFOZ=::QH
MNH:?J^DZA!'=:?JFE7MOJ&G7]M+DQW%G>VCRVUS`ZX*30RR(W.#QDY0K0FW!
M3@ZD4G.$9*3C?:ZT?X>0&G1116H!17DVK?'CX*^'M4OM#\1?%SX8Z!K6F3_9
MM0T?6?'OA73-4L;C8DGD7NGWVJ6]W:S>7)')Y<T2/LD1P-K`GTRPU"SU.TM[
M^PNK:]L;R"&ZM+RTN(KFUNK:X198+BWN(6:*:":)TDAFB9HY8W5T=E8&LJ=>
MC5<HTZL)RC;F49)N-^Z6J`NT45R/BKQ]X(\#QV4OC/QAX6\)Q:B\T=C+XG\0
MZ1H$5Y)`BR3):R:K=VJW+Q1NKR)"9'16#,H4YIU:L*,'4J24(1WD]$OF!UU%
M<QX5\8^$_&MC-J?@[Q-X>\5:;!<&TFU#PWK>G:[917:QI,]I-=:9<7$$5U'%
M-#*]N[B58YHW*[74G+\2_$[X<^"[J"P\8^/?!?A&]N[?[79VGB7Q5H6@W5U:
M^;)`;JWM]5OK.6:W$T4D1FB5T$B.A8,I%3*O2A%5)5*<:37\24TETM;H_O0:
MO1*[.[HKR+_A?_P+_P"BS_";_P`./X/_`/EQ1_PO_P"!?_19_A-_X<?P?_\`
M+BL_KV#_`.@FC_X,C_F.S[/[CUVBO(O^%_\`P*_Z+/\`"?\`#XC>#OZZR*]2
MLKVWU"V@O;.>"ZL[J&&YM;JVF2XM[FWGC66&XMYXR8IH9HG22*6-FCD1@R,R
MD$ZTJ]&M?V-6%3EMS<DE*U]KV[A9K=-?(MT5C:_XAT/PKI-YKWB36-*T#1-.
MB$VH:QK>H6FE:781-)'"LMYJ%]+!:6L332QQ"2>:-#))'&"7=0</P?\`$?X?
M_$!;]O`WCGPAXS72C;KJ;>%/$FC>(1IYNUE:U%\='O;P6IN5@F:W\\Q^>L,A
MC#!&P2K4XU(4I5*:J33<8.24Y6M=QCO)*^OJA:[VT.UHHHK4`HK$U[Q)X?\`
M"]A)JGB37-&\/Z;"K--J&N:I9:38Q!<$F2[OY[>!`!DDM(``.OKX'/\`MB?L
MGVUVUE<?M)?`Z&Y1_+:%_BGX+#I(.J./[7PK#TR<^V.>>MB\-0:5;$4*+E>R
MJUJ=-NS2=E.2;M=7MMI?<:C-_#%M>C[K_@_U<^EZ*X?P?\2_A[\0(&N?`_CK
MP?XQ@54=IO"WB71M?1%=2Z[VTJ\N@GRC/S$''7!S7<5I2JTZT%.E.%2+^U3D
MIQ?HT(**,UX5XU_::_9X^&EX^G_$#XW_``H\'7\>_P`[3_$/C[POI=_&4P6#
MV-SJ,5VK`'A&A#MV7M45\31PRYJU6E2CUE5JTZ45MNYRCWZ?Y#LWLG]Q[K17
MRKI?[<7['VM3K;:9^TW\#;J=F"+&OQ+\*1LSE@JHOG:K'N8L0!MSCOC(KZ*\
M.^*_#/BZQ34_"WB'0_$>G2*K)?Z#J^GZQ9.&S@I=:=<7$#`X."'P>Q-10QV$
MQ+DL/BL/6<;<RI5Z55KFO:ZA)M7L[7WMH.4)Q^*+7JOZ[G04445U$A7SG^UU
MK5UX<_94_:6\0V3%+S0?V?OC)K-JZL4=;C3?ASXBO("C`AE(EA4[E(96VD$5
M]&5\\_M9Z#=^*?V6_P!I#PQ8QO)>^(_@)\8-"M(XU+2/<ZK\._$-C;HBCDN9
M9P%4<LQ`QS7#F7M/J.+]E_%^JXGDWW]A.UO.]C2E_%I_]?(?^E(_F`_X-YM`
MM;[]J/XP^(95!NM$^!EUI]HQ`+1#7O''A%KB6/(.U]FD)%O&"$E=<D.5/]@M
M?QY?\&]7B6UT_P#:I^+7AN9U2X\0_`R_O;(,5'G2^'_&WA`RVZ$D9D,&J23[
M0?\`5V\KGY48C^PVOB?"]TWPI0]G_P!!>-YEV?UB=K^?Z6.G,/\`>);[+>^U
MEW_'T"BBBOT0X@HHHH`****`"BBB@#P3]J+PY;^+_P!FSX_>%KJ/S8/$'P5^
M*6D.FS>W_$P\$:S;J\:X/[Z.219(&&62549<$!E_EC_X-[M<FM/VMOBEX>#9
MM==^`6MW<L9=E#7&B>//`1MI0HX9HX]2NE#-RJRN!P[5_4G^U=XGMO!?[,/[
M0WBR[D$</A_X)?%+5.7V&2:T\#ZT]O;JV1B:YN1%;P#<"9Y8@#D@'^7+_@WL
M\/S7G[5WQ8\3;6%IH'P&U33I91'N5;GQ!X[\$-:Q;\91I(M'O'4!AO2&0G.S
MC\PXIUXXX']E;VOML3[7;^%RU?8_^Y/Z1WX6_P!3Q?;DC]^G_`/[$:_GP_X.
M(21^S3\$<`9/QT(YS_T(/BWZCU[?I7]!]?SW_P#!Q'_R;3\$.W_%]#^7_"`^
M+>_^<=:]_CYVX2SI_P#4*O\`T_1,,)_O-'_KXC^?OX">)OVFOV*+#X2_MH_#
M!I$\!^.=4\1>%;J8?:KKPKKDWAO5KJVUSX=?$"RC"+"VJV%I%K6B7!D5@LGV
MO2;R+5-(O%MO[5/V,OVS_A1^VM\*[7XA?#R\33]9T];:R\>>`K^YC?Q#X'\0
M/&SR6%_&JQ&[TRY\N2;1=;AA2TU:T5F"V]Y!>V-I^8__``1V^%/P_P#V@_\`
M@F?XH^$?Q3T"T\4^"M;^*_Q&T;5-,NE*2IYEIX8U*SU&PN5)ET[5M,O9X[_2
M]1LC#<V%[!;W4#B5-[?D-\<?@5^TY_P1S_:3T7XK?"S5]1UCX8ZKJ4]KX2\8
MW%M-+X=\9>&YWDNK_P"&7Q0L+5XK>'5X[6+=(JF!;U[6'Q/X8FM-3M&@T?\`
M/LCK9GP=EV5YQ257&\,9EA,-B,RPZ?-6R[$U*<85*])-/F4W&\HKE4N5)M<I
MVUU#%3J0ERPQ5.;A%REIR*R271N*TUMNC]+O^#C*WD?X7?LRW0C4I#X_\>V[
M2'!9&N?#NBRQJ%X9@_V1F95ZF-03R*^X/^")AS_P3K^#QX_Y&/XK@8Z<?$[Q
M9W_'GBOR-_X*K_M9?#7]MO\`8?\`V=?C+\/)C9ZCH/QFG\.^/_!EU<)-K'@7
MQ1J_@#6M0.E:DJK%]HT^];1)YM`UL116NJV,;R+';7L%_I]C^N7_``1,_P"4
M=?P>QW\2?%G''_53O%G^3[UZ^3XJCC?$K'XO#58UL/B>'J%>A.#O"5*I+`<D
MEYNTDXO:U]-C*M"4,#&$E:4<0HM?X?\`AS]8Z_GD_P""K7_!6?Q'\`?$NH?L
MX_LY36-O\4;&SB_X6'\0[F"'4XO`S:I9I>6?A_PS8W"R6=SXI^Q36UYJ&IZA
M!<V&C)=6UM#:W6JFY73?Z&Z_SY_VT=&U?P!_P4)^/'_"SK:YEC@_:-U[Q7J<
M=W')*VJ>#]=\8/XLT:ZAB=09K#4_"&J6;VL$6(#;R+:1[5!">MXD9QC\JRC#
M0P-5X5YCB_J=?&17OX>BZ<IR=*7_`"[JSY>6$_LV;LW:V>"I0JU7[17C&$I<
MO>UM#]O_`-F'_@CKXF_:%T31OCI^W_\`%SXI^+?&'B^RL_$%I\/(_$MVVH:7
MIFJ(M[:VWBSQ'K']IW]M?RQRAKKP]H4&FQ:.66S:_>XAEBM_T$G_`."+7_!/
M*;2_[-7X-:G;OL"?VI!\1?B`NJ9'1S/)XCD@9AD_*]LT9)Y3'%?I[H.MZ3XC
MT;2]?T&^L]3T+6M.L=6T?4]/GCN+#4=,U&W2YL;VSGB)BEM;JWDCFMY(V*21
M2(R]:U\CU%>S@>#N'\-AX0G@,/CJLHQE6QF-C]:Q.(J27O5:E:K*;?-T2LEW
M9E/$5G)N-25)/:$':,;=$NG]:'Y=_LS_`/!)/]F7]EGXMO\`%_P!J_Q/U35[
M6"2+P]HOB7Q:D^@Z!-,K13WBVVCZ?HTVMS&!W@MXO$$VIV5LKF9+4W:6]Q!^
MHM&:*]W`9;@LKHO#X##4L+0<G/V5&"A!2?Q.R[F4IRG)RF^:3W=NVVWD?A/_
M`,%>_P#@ICXD_92M]$^!OP1FL[7XS>,O#_\`PD.M>+;B&*_'P[\)7MW/I]E+
MIUC/'+9W/BG6YK/4'L3J,<EOH^GVG]H26=S/?:>4^3OV(O\`@E%-^U_X"\/_
M`+4?[;7Q3^*'C6]^)$!\2^%/""^)KL:C=>&;V1GTW6?$WB74UU#4(TUN(?;]
M+T?0!IJ66D3V,CWQEG:TM?@O_@N5X8\1Z)^WSXMUK6()UTCQEX`^'&M>$[AU
M?R)M)L/#T/AB^BMV(V?N/$.B:L9(E8LC7",P'G(6_J]_8&\8:'XY_8O_`&9=
M>\.S03::OP2^'6A.+=T9+?5O"OARR\+:_8OY8"K/8:[HVI6ERF`5GAE!`Q7Y
M;E\/]9N-\]PF=RE6P>4*4<#EKE4CA)\LZ</;UJ4)P56JE)-RFGS=$K,]&K%8
M?!T*E)VJ5N5RJ+XE?5*+UM;7IKY/?YPD_P"",'_!/"2P%A_PI*^0A#']N3XB
M_$,7_0KO$Q\4&,.,YRL`![KTQ^4G[<W_``2[\2?L/>#=3_:G_8E^*WQ0\-:?
MX$>WU+QIX5_X2.XCU_1-%DN8H/[>T37]*73Y=6TC2[B>`:QH^N6]T\.E//J,
ME]>6]I=6K_U4Y'3(S7R=^W9J>BZ3^QC^U'=^();6/2S\`_BK9R&Z*B*2ZU'P
M9JVGZ7;*&8+)<76JW5E;6L993)<S1*OS$5];G?"N13RW&3HX##X'$4,+B*V'
MQ>"A]4KX>K3I<\:D*E!TGHX)6DWOI;5/GH8FLJL%.I*I&4HQ<9N\7=I:I[VU
M:/S9_P""1?\`P4W\2_M7-J_P+^-_V*7XQ^%/#I\0Z'XOM((K"/XA^&M.N;73
M]1_M&P@2.SM/%>D2WEK<W@TV.*SU73IY-0BL[22QO]_[L5_#A_P1`TG6=2_X
M*#_#N\TM)C9:%X*^)VJ>(7C4LD>D2^$+_18?M!Z+#)KVK:+""Q`\^2%0"Q7'
M]Q]<GAQFV-S?AU5L?4]M6PV*J815FO?K4Z=.C.,ZC^U4_>.,IWO)QOH5CZ,*
M-?EIZ1<(RMVOT_#R/Y)_^#BG_DMW[.__`&2OQ)_ZEK5^]?\`P3(_Y,'_`&6O
M^R5:1_Z5W]?@I_P<4_\`);OV=_\`LEGB3_U+3^5?O5_P3(./V!_V6N0/^+5:
M1U_Z^K^O'R!_\;'XL_[!8_\`I."*KO\`V"A_U\7Y(^[J**`<].?I7ZK==U_7
M_#G`?C-_P4]_X)<>&?VN]"NOBI\*[73_``U^T=H6GL(KC$5EI'Q2T^RC'D>'
MO$\FWR;;6[>%?)\.^)7_`'D#B'3]8>;25BFTS\D?^":W_!2SQK^QYXS;]E']
MJ^+7=.^&>FZ]<^&[*]\1P7:>(O@AXA%W):SV%_!.&NI/`YNG/VVSC#R:"[S:
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M3O\`P6@_:9U7XD_$C5+_`,,_"/PS?166OZ]:12GPO\/?#(F%U:?#WX<V=T#;
MZCXHOK8I+//,&=?M`\1>(GD!LK&^^6?V+?@CXZ_;^^/WPI^`?C3XF^(8/!?@
M7PIJLR7.H7UQJMSX5^&_A^];5=1\.^#+2[>2ULKK4;_5([2R#(;6R-T;Z6&:
MUTRWL5_NT^#OP<^'7P$^'OA[X6_"OPU8^%?!7ABS6TTS2[)/G=R2]UJ&HW39
MGU+5M2N&DO-3U2\>6\O[R:6XN)7=LUXN`ECO$>K#%8Z+P/#6!JQC_9\*T:E7
M'XZG"E.<,3*FUS48.=G!QL^:Z:=TKJ*.!O"*YJ\HRC.;TLGRVM&S3M9]5KWU
M*7P/^!_PW_9V^''AWX4_"CP[:>&O!WANS2WM+2!%-U?7>!]LUG6+W`FU36M4
MD'VC4M2NF>>YG)8E8Q'%'\R_M3_\$W_V9?VQ?&>@_$#XU:1XKO?$WAOPU'X2
MTZZ\.^++_P`/V_\`8D6JZCK,4-Q:P)-!--'?ZMJ$J7`1)2EQY4A=(H1'][45
M^HU\KP&*PD<#B,)0JX2'L^3#SIITH^ROR6A_=N^OXZG!&4H24X-QDMFMUW/Y
MW?VP/^".7[%WP:_9>^.WQ4\#:+\0K/QAX`^&GB7Q7X=N+_QY>ZE91:KHUB]W
M:-<V5Q:>5<PL\8CFB8J6A=T5T+;J_)K_`()"_L8?!7]L[XG?%OPS\;+3Q'>Z
M/X+\"Z1KNC0^'==FT&4:EJ.OII\DMS<6\,LLT:6RLJ0AHUS(S$DA=O\`5M_P
M43_Y,5_:L[_\60\=]O\`J"S_`%_SZ5_/U_P;JG_B]G[1`X_Y)=X8_P#4M^HR
M/ZG-?DN>9'E%'CGAC`TLOPM+"8JE7]OAZ=/EI5=,4Y.4%9.[\E;\#T\/6K/!
M8ANI)RC.$8.6MM$VTM%=W]-#]1%_X(5?L!*?^1<^)V,C<I^).J`,`0=K8M@P
M!QSM*MZ$5^N_ASP]I?A30M&\-:%;)8Z)X?TK3]$T>QBW&.RTO2[2&QL+2-G9
MW:.VM8(H8R[%MB#<Q/-;=%?JN!R7*LLE4GE^!P^$E5BHU'0IJ#G%;*5K7MJU
MV;9YTZM2I;VDY3MM=WM>W^2/S-_X+#?\HX/VD.W^@_#/\?\`B\GP[X_^M_\`
MKK\F/^#<4DZ]^UKP,C2_@K_Z5?$T>G'Y5^L__!8;_E'!^TAG_GQ^&?;I_P`7
ME^'7^>W]#^2W_!N)G^WOVMO^P7\%>>W_`!]_$WMW_/WK\]SAO_B*'#VNG]ES
M>KLM\9M_7?J=M#_<<1_U]A_[8?U-U^)/_!5G_@J'/^Q\FF_!WX/VVE:O\=O$
MNBC7;O5=40:AH_PV\.WIFAT_4[K3@0FI>)-5FM;F31]+NB+.TM+<:KJ<-W!/
M86&H_MM7\(G_``63\,^*_#__``4'^-=]XGANQ:^*X/`OB/PI>W`D\B_\,'P/
MX?T.V:P:0`-;6&IZ+JFCLL:JB76GW"89]SO['B+G./R7(8U<NYH5L5BJ>%EB
M(Z/#TYPJ3E4C+[%1\EH3L^7WFE>QG@:,*U?EJ:Q4)2L[ZM6TT:[GZ-_LD?\`
M!,WXN?M[>&M%_:<_;H^./Q2U70/&L?\`;?@CP3!K+?V]JGAVYE,EEK=W<ZG#
M>:1X/T/58P;G1=$T#1$FFTJ6TOQ<:?#<10M^I5M_P19_X)Y6^F?V<_P;U2[D
MV;#JEW\1?B"^J<@;I%GC\20P)(S#=\ELJ*20L87BOM']E3Q/X8\8_LU?`CQ#
MX-NK*Z\-7_PC^'O]E-8&(P6\-KX5TZRDL&2%BMM<Z=<6T^GW=DP6:RNK:6TG
M1)H70?0FX>H_,5V91PGD$<!AJE7"T,SK5\/0JUL;C.;&5L14G3C4E4=2K.>C
M<K))1^%<UWHL:E>M[22C4E3C=6A!VC%>2Z/3TO\`C^2?PB_X(R?LE?!7XQZ#
M\8?!M_\`%;S_``U.-0T?PAJ7C9W\.V^KQR;[2^N+C3=.TW7]0ALW"R1:;?:Q
M<6,[JHU"*]@W0-^MM&:*^CR_+,ORNG.EE^%HX6G4J.K.%&*C%REULM%MI;0S
MG5J5+>TFY\NBOTO:_P!]C^9G_@NY^U3^T5\,O$/P\^"7P]U+Q-X`^%?C#P5/
MXC\1>,_#TEWI=UXXUR74]8TV]\%_\)%9M'-:6&A:;8V6I:II=G/:3ZDVNP?V
MAYNGK;I+S'_!,C_@GQ_P3X^/?P9\,?$'XC^,HOC1\7M;BNKSQEX%O?'ESX;;
MP1?-?W,2:-+X6T;4=*\0W3-;)!,VMZE>75CJS3?;-*$5JXW?T?\`Q:^#?PQ^
M.O@^]\!?%GP7X?\`'?A'4`3/H_B"PBO88YPI6*]L9CMNM,U&VR7M=2TZ>UO[
M5QNM[B-B37X>?%C_`(-^_@OK&NW'B'X%_&?QW\('DD>>WT+4K"#QOIVG2,Q?
MR]*U(:EX?\0V]LF1L2_U/5+@$*?M9&17YSG'#6;0X@JY['"8;B;"58N%+*\;
M7C1E@(SY;_5H5%6H5G%Q3ESTO>]VW)9M]=*M3]BJ3E.ARNW-!N7/>WQ)6M:V
M]WN]NOUWXI_X(N_\$]?$U@UI:_!_4_"DY5U34O"_C_QQ;7T3,"`ZKJNNZO8R
M%<L52ZLKB(G!>-]HQB_LQ_\`!'_X)?LL_&RW^,'@KXH?&'5K?2[>8Z-X(U;Q
M%!8:-'J<X,27VN7/AJ#1)/$]K:V[-':Z3JMNU@9=D]]'?F&!(_SCU7_@F-_P
M52^`=B^K?L]?MAZEXUM],0W%IX9A^(/C+PK=W<<.7^SP:!XLGU;P?<R2!0?L
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M"M^S#K$_[!'_``51TGPUXFN#I?A_P;\9O%/P>\275X3!;2>"_&5QJ7AG2-?N
MV8J!IZ6&K>&O&*2.^U;2*"5F#\#^Z@$$9!!!Y!'(YY'YCFOY._\`@OK^RA>>
M'?'?@W]K;PKISMHGC>VL/`/Q.FM8FQ8>+M"MW7PEXAO&B!8)K_AVV70O.+H+
M>Z\+Z9&7,NI1U^O/_!*#]M"Q_:S_`&:]&LO$&J13?&+X26>E^"OB19S3*;[5
M(;2T-MX8\<>63YKV_BG3+,M?7!15'B&SUM?+BA,`/Y1P;7CP[G>=\(XCW8O%
MU,PRF[LJM&K\5&,FESU=(.$=+KF[:^AB8^VI4L3%\SY5"JU]FUE!]];RUMZ7
M/U,HHS17ZN>>%%%%`!1110`445#//';1//-)'%#$CRRRRN(XXHHD,DDDDC85
M$1%9F9B``,D@9-#=M].NO9;OY`?CQ_P7!^.5E\*_V)?$'@FVO4@\3_'+Q%HO
M@#2K=)=ES_8EG>0>)_&%[Y:D,]D-'T==!N^B--XALX'($_/R_P#\&\_P=N-"
M^#OQL^-^I6C1/\1?&6B>"?#\LT6'ET3X?Z?>7VHWMNS$EX+W6O%LNGS,25,W
MA\QX_<[F_)[_`(*3?M(>(/\`@H3^V=H'PZ^#4<WB7P?X7UFV^$'P>L+)FEM?
M%.O:OJUO;:_XQ@8;DCM?$&K^1%;WK")8_"N@:;J-SY8>ZA7^PO\`9>^!6@_L
MT_`;X9?`_P`.LLUEX"\,6.EWFH+'Y0UC7[AI=3\4:X8^J/K?B2^U356C8EH1
M=B#(2-57\HR>HN)>.<9GD'SY7D%)X'"UDKPJ8J;5-<FRTE4KU6];.48^9WU+
M4,)&A)MU:MJKCLDG9VOKV71:>6_T'7XJ_P#!;C]GGXT?M%?`/X3^'?@I\/\`
M6OB)KF@?%U-<UC2]#-E]KL-'?P=XET_[>\5Y=6WF0+>7=M;L(2[*\\>Y0#FO
MVJHK]#SG*Z.=9=BLLQ%6=*CBZ7LYRIJ'/I.$TX\\9;.&RMOOHCDI5'2G&:5W
M'IL?D?\`\$8?@C\8/@!^RAXA\"_&GP)K7P]\3S_&3Q9X@L-%UUK$WDVAZAX:
M\%6=M?JMC=WBI#->Z9J$*"5XY";=G\L(RY_2;XN_"+X??'7X?^(OA?\`%'PY
M8^*O!7BFQ>RU;2;U.IRLEM?65PN)[#4].N$CO-,U*T>*\T^]AANK6:.:)'7T
MK-%+`Y3AL#E6&RE+V^%P^&CA>6NN=5*225IIO6]M-=.@IS<ZDZEDN>7-;HKV
M^_8_B4_:D_X(Y_M:?"#XC:_X5^!GA#Q5\;/@]KMU%K>@:OH%QIT=Y##:'4$T
MS2_&ND37UBG_``D>@I>SVUKJD%O)8:A:7,][8-9W%[?V5G_27_P2B^$WQ(^"
M'[$'PO\`AQ\5O">H^"?&VD:M\1;S4_#>K-:M?V,.L^/_`!+JNGM<?8Y[F!?M
M-A=VUU&@EWK',@D2-^*_2"BO`R3@?*\@S7$9GE]7$Q]O2J45A:D_:4*%.=2E
M4]G1<KU/9KV2483G-1NVFKM/:IB9U:4:<HQM%IW2LW9:72T"OR\_X*`_\$Q/
MA5^V]IMCXB;4W^'OQIT#2SIF@?$/3[%+RVU/3H6EFM=!\8Z2LD#:KI5O//*U
ME=VUQ;:MI9ED^S74ELTMG)^H=%?2YCEN#S;#3P6/HPQ&&J+WZ4XIVE]FI![P
MJ0UY)K579A"<Z<E.#Y9+9_UZ'\OWPC^'_P#P68_X)\6@\">#/`OA[]I?X-:7
M,_\`8V@VNL0^)K#2[1Y'(7PW%/J7AKQYX>CDV^:VCK:7VBV<\CR06DC$R-]2
MV'_!2;_@H5>J=+C_`."6OQ(.OJBH\LFM^)+#1C*6!#"6\\%1(L6"7(.H;E^Z
M7?;NK]W**^=PW"F(RZG[#+N)<ZPN$3_=X:K'+L="A'2U.C4QN"K5:=.-O=AS
MNW?16V==2UG2@Y]91O&^WQ)7OM_PY^1'P`^*W_!6'Q_\6]!U?XP?LZ_!7X5_
M`^<FU\1>'K[Q68_&<%A/+&RZUI-[INK>+KR\UG3HV9ETK4-)TK3;_?-:7#:=
M,8;R#]=Z**^@RW`U,!1E2JYCCLQE*;G[7'3HSG!RM>%/V5&ERTT_A@^;EOH]
M=<IR4K6A&%OY5:^V_I8^%_VY/V$/A1^V_P##RR\*^-FN?#WC'PR;V[^'_P`1
M='MH9=:\,7MY"(KJUG@D,<>L:!J*QP)JFC3S0"811W-I=65[##=)^,/P3^#/
M_!6?_@F?+K7@WX8?#KPQ^T]\#;_5YM8BT'2-3^VPVMS-L2;4='TN:_T7QCX8
MU+4(HXCJ-C;V.OZ$TJ";RKBX5YY/ZAJ*\G,N%<!F&-AFE&MBLLS:"Y?[0P$X
M0JU(:7IXB%2%2E7I.RO"I%I=&KN^D*\X15-J,Z:=U":NEML[W1^&*_\`!3C]
MN2.'[-<?\$L/C*VKC$9:'5O%']G?:3GGS#\.)/W(;:"XN&4Y)#\&OD_X\^"?
M^"NW_!2.SMOAMXG^"WA_]F3X(7&IVM]JVF:_K4>EIJ1L;F.YLG\4W$UYJ?C3
MQ%'ITN+VRT[3/#FF:1+J4%I=7%IYELEQ!_3]FBN?$<+8G'4987,N(\VQ6#J.
M/ML-"&!P4:\5_P`NZU3"X:G5E3E]J"G%/0<:ZA)3ITH*2V<KSMMLGHMOZZ_G
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M_#<G_!8#_I&]HW_@SUK_`.:NOUN_9C\9_&3X@?!7PCXN^/OP[T[X3_%+6H]7
MN/$'@#2[R6_@\/P1:[J=GHL<T\US>2"]OM$MM.U*[MS<S&TGO9+61EFAEBC^
M@:*]?+<IQN!K2JXC/,QS*+IN$:.+CA?9Q;M[Z=*A3J75K)1G%/K>R2RJ3C-)
M*G"FNO(M[6MO?M^+"O!?VH/#6N^-/V;?C[X,\+:;-J_B;Q;\%OBEX9\/:3`T
M:3:GKNN>!];TW2=/A>=XX4FO=0N;>UB,TL46^10TB9S7O.1ZBEKUZ]&&(HU:
M%3X*M*I2G;27+5@X.SO[K]ZZWO:QFG:2EVZ?-/\`0_E%_P""/'[$O[5?P$_:
M^_X6!\8?@EXM\`>#X/A;XUTEM>UXZ7':-J6HW6@?8[&,6NHW4[W%PL$[J!"5
M6.&1W90!G^KJBBO'X=X?PO#67_V=@ZM:K1]O4K\U?D<^:IRWUA"-_A5V[W\C
M:O7E7GSRT?+&-O3_`#"BBBO>,3Y4_;?\&>*OB-^R+^T1X"\$:)=>(_%_B[X2
M>,M#\.:'8M"MYJNK7NDS1V=A;&XD@@\ZYE811^;-&ID9%+9;-?B]_P`$0_V2
M?VDOV</BG\<?$'QN^$?B?X<Z3X@^'_AW2=$O-?\`[.5-3U&W\127L]M:+9WU
MW,\L-NF]R8UC4.NZ169$?^DRBOGL;PYA,=GF6Y].MB*>)RRG.E2IP</93C/V
ME^92C)IKVEURVVUO?3:-:<*,Z,=%.7,WK?II^'^04445]"8GP/\`\%.OAEX^
M^,?[#7QS^&WPP\,WWC#QQXEL?`PT3PYIAMUO]3.D?$[P3KM^EN;J:"$O!I>F
MWUTRO*I,<#!-TA2-_P`W?^"&W[*W[0G[-NI_M(WOQP^%WB+X<0>+[+X56OAM
MO$']GH^L3:++X]EU46D5E>WC[+'^UM/\^63RU!G"KN*N%_H:HKYS$\-87%9_
M@>(9U\1'%8##2PU*E!P]C*$O;7<E*,K/]\]DOAWUTV5:4:,Z*T4Y<S?HE96^
M7XA7P3^W3^P%\(_VX_!%CH_C5[CPSX[\,17+^`_B3HUM!/K&@27"9N=,O[24
MQ1:]X;OY`DE[HMS-`5D7[7I]Y879>=_O:C.>E>OCL#A<RPU7!XVE"OAJT7"K
M3J1334M%*+^Q4C]B:UBWH9PG*G)3@^64=G;8_EH^%_[,W_!7O_@G%>ZCI'P&
MMO#/[0WP<?4)]1/@ZUU*UU/1)S)++)+>VGA77=4\.>+/"^L78.Z]A\)WUW:7
M<[K+=-J<L9>OK+2O^"D__!0^%8])U?\`X);?$:Z\0E=CSZ9J?BJRT>290!N7
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ME@@LTCDEN+FZF?R_GK1O^"CW_!4'P@8['XG?\$V/$?B6XB15EO\`P5IGCG2H
MIF4!7<)#9>.K)C(,,HBNXHP&.`=G/]"=%>37X>QTL37Q.$XESC"2KS]HZ3>%
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MC*-&$://\4H?&[;6F]5;\=F(JA!A0`.``!@`````=@```.U.HHK[(Y0HHHH`
M\I^-OP:\#_M`_"_QG\(?B1IHU7P;XXT.[T75K8!%NK=Y3'-8:OIMPZ2?9-8T
M2_@MM5TB\"-]EU&UMK@I)Y06OXE-3T_]HW_@C[^V6EQ;J]Y;V$T[:==7,5Q9
M^$/C3\)KV^622VF(:95E,-K']K@5YK[PGXLL$GB2XAL[6\OO[P:^4OVM_P!C
M_P"$7[9'PPNOAO\`%/3',D'GWO@_QCIB11>*/`VO/%LBU?0;QHV/E.PCCU/3
M+CS;#5K4"&[A:2.VN+?XGB[A>IG-/#X[+JWU/.LME[7`XF%X.HUR_N*TT[N,
MN5<LK/EU]UW.K"UXT9RC45Z56/)4UMUT?RNRU^R=^UQ\(OVPOA=8?$SX5:S#
M*/+MK?Q3X2O9X5\4>"->DBWSZ)XAL5;?"ZE7:POXU:PU:U`N[&9T\Q(OJ.OX
M3OBO\`OVV_\`@DI\98?'WA76=:TWP^;PV?AWXM^%+2YO/A]XYTEIA-%X?\::
M1<?:=/M+JZC@@%]X3\2HQ:[C:XT&_OS;6NIK^UO[)W_!>;X(_$*RTSPS^TWH
M=Q\&O&K+#;W'C+1[74-?^&FL7)"1B[,5I'>>)?"QNIGP+6[L]8T^V!WW&N1P
MCY/-R3C[#N3RKB:$LGSG#R=*H\2O9X3$.*5ZBKM*E2OH^64K/F]UNSM=;`N-
MZF'<:M*6L8P=W%*V^E^J[]?5_P!`E%>;_#CXO_"WXNZ2NN?##XB^"?B#I+)'
M*+_P=XFT?Q##&DJAD%R-,NKA[27!&Z&Y6*9&^5T4\5Z/D>HK]#HUJ=>"J4JE
M.K![3IR4HOT:.+7L+14<LT4$;RS21PQ1HTDDDKK''&B@EG=W(5$4`EF8@``D
MG%?!?[0/_!2[]CC]F^POO^$U^,?AOQ!XCM%E6+P/\.[RW\<^*[BXBW`VDUKH
MDTVG:)*2C_-XDU+1H!L=3+Y@$;8XO'X/`4W6QF*P^%HQOS5*]:%)*UM$I-.3
MUV5VNNY4(3J2481<I/9*_P"=NF_IJ?>Y(`))``Y)/``]23P*_E]_X*[_`/!5
MC2[W2_$W[*/[-GB&#4#?I<Z)\8OB?HEX);)+$N]MJ7P_\'ZA:OY=W-=X:P\6
MZY;S&U2R>ZT*Q:[DO+XV_P`:?MC_`/!7S]H?]L&\E^#GP%\.Z[\+_AUXIO!H
M<'ASPHU[K7Q5^(<=Y(;:/3-5U'1HC<P6NJ(XBF\*>&(LW,;W-IJFJ:M:.57[
MG_X)J?\`!&&;PWJ&A?'C]L/1K>76;)[36?!/P0N_)OK/2KQ62YM=:^)#*TUK
M?W]M(!-9^$K=I;:WF*3>(I9[SS='L?R_->),QXNJO(^$HU(86?\`R,,]E>&'
MI8>Z4X4II-WE9JZ=Y)674[Z>'AATJV*=G=>SI)7E/:]KVO:ZO=;.YUG_``1/
M_P""=-]\.K"W_:[^-&B26'C7Q'I,D/P:\+ZG:;+[POX6UFU*7OCC4;>8;[37
M/%&G3&ST.`JDMAX;N;JYG\XZ\L-E_1W444*0J$0`*JA5``4*JD[5`7"@*#@`
M`<`9R>:EK]!R#(\)P]EE#+<&DZ=-<]6I:TZ]>:7M:\]7K-I:7=E;5G%5JRK3
ME.772*_EBMHWZV[V7H%?G?\`M_?MPZM^Q=IOP7DT/X>:/X_U+XQ>/9O`T"^(
M/%\G@S1]`=+>QD35-2U6+1-;"V2RW\7VR>2&-+.TCFN<RL@A?]$*_+7_`(*;
M_L8_$[]L+2_@%#\-9OAU)+\)OB3=>,]?T/XEWNL6.@^)=*:WTU1HLATG0M>:
M:"^DLOLNH0W-JL36$\^QGDVQ/'$<LRAE.)GE*G+'Q=%4(P4')WQ%%5;*I&:U
MI<\-M%-O=(='V?M8^V7[O[7?I;_,P/C5^W]\9_V=_!-]X]^(GPY_94\0:9I>
MR6Y\-_#W]KW[5XYU.%KB&$Q^&?#?B;X2:&WB+4567>NF:?<RW<XCE,2$(-WZ
M%?`?XLK\<OA)X%^*R>#?%?@!?'&@6NO1^$?&]BFG>)='CNGG2.+4+6*691'<
MI"+[3Y\QF\TNZL;UH+<W'D)^87Q._8T^,OQ&\%^(/">F_L?_`/!.?P%JNLZ5
M>:?IOC:UF\4ZGJ_A>YN56--;T2'2/@WX6OUUC36'VO2IX-<L/LNH16MT6ECA
M>WG^WOV(OV>_'G[,7P)T?X4_$;XPZ_\`&SQ'8:GJ.J/XFUQ;M8=(M-16U\GP
MGH!U*[U#5&\/:0]O-)8MJ-[/<&2]N3%'96?V6PM?+RJIG:S*<<1#$SRVI@U)
M59TZ%.-'$1M9N?)0KU?:IO2G1FJ?)[_*IKFNI&GRWA)W3UC_`.`KN]>]WT/K
MZN2\=^)_^$,\%^+?%HL_[1_X1CPQKWB(6/F^0+PZ)I5WJGV0S!)3#]H%KY0E
M$,WE[M_EMC!ZVN*^(_A^[\6^`O&OA2PDAAO?$_A'Q+X>M)[DR"VM[G6-&O=/
MMYK@Q*\@@CFN4:8QI)((@Q1&(Q7U5=572J*@_P!ZZ514V]/WEER7OUO?\;G.
M?,G[!O[6%S^V;^SWI'QPO?!<'@*XU+Q%XGT"7P];ZU)K\4)\.ZB;$7*ZC+IV
MELRW2XE\HVO[HD@.XP:^T*^!?^";7[,'CO\`9$_9AT/X+_$;5?#>L>*-.\4^
M+]?N;SPI<:E=Z-]G\0:J]S:00W&JZ;I%Y)-#`J?:-]C$BRLR)D*6/WU7#DKQ
MKRO`2S%../EA*+QD9)*7MW'WV[:+T7SML:573=27LE:G?W?2P5^9\W_!0#6O
MB?\`'SXA_LY_LH_"&W^+GB?X02O9_%?X@^,_&X^'?PP\&ZO#J4^D7&BQ7EGX
M?\7>)/$6HV^J6FH:?-'IV@Q)]KTO4Q;O<VUE-<K^F%?DCHO[#7Q>_9L_:8^+
MG[17[)/B;P#K.A_'B[N-5^)_P5^+[Z_HFFQZ_/JU]XB;6/!_CWPOIGB"^TUQ
MK&JZO/;Z=J?AJ_M+*'5;FU#74:V`T_#.I9FI9?\`4556&^M/^TI8:%.>+CAE
M2DX+#QJJ5-^TK*%.HG%M1GS+X;,I^SU4[N6G(MD]?>N_*ZMT/6OBW^TE^V!^
MSYX(UOXI_$3]F[X6^/?A_P"$].GUOQB/@_\`&;7I_&>A>'[!//UC6[70/&OP
MT\/6&NVNDV2RWUU;6FM6UZ;:&1U@V)+)%]/_`+.'[0WP\_:C^$OACXS?"^]N
M;OPGXGBN5BBU"W^QZMI>IZ=>7&GZMHVKV8EG2VU'3KRW>*98I[BVF1HKJRN;
MNQGMKNX^3/COX3_;U_:"^%OC'X/P>#_V>/@EI/Q"\/:KX/\`$WCB#XK>/OBE
MKMEX;U^SDT[7CX;\/6_PI^']FNI7NF7%S9VSZCK?DPK/(6W2F)U]_P#V-OV7
M/"W['WP$\*?`[PMK.H^(XM"DU'5=:\2ZK"EK=Z_XDUV\DU#5]2^PQ/+#IUJ9
M72UT_3DFN&L].MK6*>ZO+D2WD_)@JN92S5J$<7+*7@VY5,=25*HL8G'D5%.G
M3K6DG+VCJ4TKJ')>[:<E#EOS)3OI&.MUI>[LK6^=W?:VOU37EOQ5U7XNZ3X?
MM)_@QX3\">,O%$FJPQ7FG?$/QKK?@;18-%^S7;W-[!J>@^#O&U[<:A'=K8PQ
M6$FEP02V\US.U\DEO%;7/J5%?1U:;JP<54G2DUI.GR\\?1RC)?@9'X^G]O3]
MJX?M9+^QM_PS?\$S\4F\$GQ]_:X^//BW_A"%T'[";L%M3/P<_MS[=N`@-JOA
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M.A7%E9ZW\1OA/\1O`>D7>IO-'IUGJGB_P;K'A_3[K4'MX;BX2RM[W489KQH(
M)IQ;)(8899`D;>WC/:_5L1*C_&CA\0Z*VO5]C-P_%$1UE%=W^J_S/SG_`&>_
M^"A/QM_:.^%>B?%CPK\,_P!EKPGHFO76L6MKHGQ%_:MU/PYXKMWT35+G2;J2
M_P!'M?@OK"VD5Q<VDLUD7O"\]FT%UL5)TS^DWP@\1?$3Q1X336?B9X?\`>'M
M:N[MY=+A^&WCO4OB)X9O_#\MO;R:=J<7B+4_!_@J1[JZE-WOMH-*GM8[=+:6
M+4+AIWCA_'7]F/\`8!^._P"S]\']`^%_B7]F']@GXRZOHM]KUY<>/_&6L^('
M\2:NFLZS>:K!#J,M[\#M8FD.F0W::7:M]N=/L=G`%CB8/G]:_@+9?%#2?"4F
MA?$KP!\)OARNAR6>F>$/#?P<\0ZSKGA:U\-VMC!'##Y.K^#?!B:/+:7"RVUO
MI^GV,]F+..!Q)!(7MT^;X>K9K*GA8YLL?]:^JR==5J4_8^V37-S3ITOJT7LH
MVK3YM;)6-:RIJ;5)W7Z=+/7S^??<]SI"0H+,0``22>``.I)I:AG@CN8I()E#
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M3Y>16M*<K2FM/OU6EGUU/J>BBBOKS`\;_:%^*C_`[X'?%OXQ1Z.GB&3X8_#O
MQAXZCT*2];3DU>3PQH5YJT>GO?K;7;6BW4EJL3SI:W#Q([.D,C*%/A?[)G[:
MWP[_`&D/@!X`^,GB#6?`?PWUGQA:ZU)J7@F\\?:)=76@W6C^)=9\/M;S3WK:
M3=-]JCTJ/4X?/TZUD%M?P?NW7;-+ZY^U#\--<^-'[.OQN^$?AJ[T^Q\0?$KX
M6^./`^C7NKO<1Z7;:KXC\/WVE6,U_):075S'9I<W2/<R06T\D4*NZQ.P"GY9
M_8S_`&`OAG\%/V;OAI\,?C)\*/@AX[^)/AFQUQ?%7BF/P+H'B+^U[W5?%FOZ
MY;2#6?$/ARVU>_\`LFEZE8:<9[R&-PUFT,:""*//S->><K.J,<)&E/*Y994=
M2=9U(4'C?K<(0M4ITZK]KR3ERTW%*2B_>5KFJ5-4I2G\?,N3O%):^;YKK[NE
MR_X)_;XTKQ[^WCXJ_8X\.>&M!U?0?#?PMB^("?%+1?&-MJ\-]J!M?#E[/H:Z
M38V,MF@MX?$"123?VT]PDT#;K0(Q*?HG7Y4_#/\`8)U?X6?\%&_&7[5?@^P^
M&OA+X+:]\'D\$:9X*\)V4FB:O:>(GM?"MK>7KZ#IVB6>@0VER^@7-U+=PZBU
MS.\T(EM_,RQ_5:NS(Y9G*EC?[5@HUEF6*5#E?-!X-<GU=TY64IT[<W+*2BWK
MHK"J>S]SV:_Y=0<]]9M.[\KZ:!1117M&84444`>#_M,?&&;]GWX!_%;XTP:`
MGB>7X:^#-8\5QZ!+?G2X]5DTVW61;-]0%K>M:+*YPTPM9BHSMC9L"LC]DSX[
M2_M,?L[?"WXZ3^'(_"4_Q&T"?69?#<.I-K$>E/!JVI:0T":DUG8/=*[:?YZN
MUG`0)/+*Y0DG[7/PFU_X[?LS_&KX.^%;S3;#Q'\1?A_KOA?1;S6I+J'2;?4=
M1MC';R:A-9VM]=0VOF!5DD@L[ET#;EA?:16'^Q/\%?$W[.G[+'P=^"7C&^T?
M4_$_P]\-W&D:S?Z!-=W&CW%U<:YJVJYL)[ZTL+N6*.+4(XB\]E;,SHY$:J5K
MQ%+,/]8%#V<UE7]E2ESM)4_KT,;!K6]^;V;=DU:VMC3E7L.:_O<ZA;KRM+6]
M^_2S_5?5=%%%>V9GX>^&O^"R^CV_QF^*7A'XL_`_6O`WP5^&_P`8]?\`@MJ?
MQWT77+CQ9H_ASQ/8:[K.D^'9O'>BV^A6MYH.E^)HM#OI(M1M[B\2RNH9;40W
MBV]Q-%];?MA?MX:?^S-H_P"SCXA\+>$])^*N@?M`?$W0_`]CK.G>+(K/3;/1
M-:CLYH/$.D:A8Z;K5KK7VBVO$GLD$MK:21HS/>*"-OF7['O[!?B+X1^+/VY_
M^%X1_#OQ]\.OVIOBG/XPT?PQ;+>ZW;R>'+O7?'^ISV'BO3M9T6QM(;LVWBO2
MT2*QGU.-+FREGBNXVCMV;Y'^+O\`P2'^+\/B_P"&_AGX`?&'2A^S#X1^,_AC
MXQV?PE^*E]KU[JOPQU?2[Z1M<T[X;Z[;:7K,]_H.K:?<W+PZ'JLVG"WU%([F
MYN[R[5M2D_.?;<9T<JJ2]C4Q>*Q6+E"DFL/1Q.7QCF4:,)2C[L:^&Q&#CS^U
MYX5*/M&G3DDF^Q/"NI'3EA#XHZM3NMKKX>7?KOTMK_0C1117Z*KV5^QQGY^_
MM!_M]>$OA#\9O!O[,?PZ\!>(/CC^TGX[ACNM(^&WAS5-+\.:7HFG26%]JR:K
MXU\8ZOYMCH%G_8^F:CK#1V]CJM\FEVC74]K`EQ9FYZH^,OV]X[>'4/\`A1'[
M-5P7,;3>'X_C_P"/(M3MHI"`\?\`:\GP2?39[B#K(5@6&0*WE,W&?%?V@_V#
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M-+35?LZ#45TR2[CANY+`78E^R/<1QSM`4\U%DW5KU];%MI-]4G^!S!1113`*
M***`.>\4>%?#WC71-1\->+-%TKQ'X=UBTEL=6T/6["TU72=3LYUVS6M_IU_!
M<V=W!(N`T4\+H<#(K\._VF/^"#/[.'Q/NK_Q'\"_$FO?`7Q%?-+<-H=O`WB[
MX<O=$M(?LV@WUY9ZWH*SRORND>(!I=I&,6VB87R9/WEHKQLUX?RG.J7LLSP=
M'$Q4>6$W!1KPCI=0K*\E>RVL:4ZM2E)2IRY>ZW3[?<?Q3>,_^")/_!0;X2ZJ
M^H_#&'PI\0/LLCRV&L?#;XB1^%]7C`95C=K7Q?)X+N+:[*;7*VVH7ZQ*-J2R
MO&&',Q_L_?\`!:[P\O\`9=I9_MBV\4&%6+2OBGXGN[)%`"J(9].\:W%DZ\$_
MN9"1GYB<K7]O]%?'2\,,IC98/-<\P--?\NJ&-3IZ6V52G*VSVMOK>R.E8VIU
MA3EZP7Z'\/,_[`/_``5V^.'EV7C7PG\:-:L)6'G3?%GXQ6$5C&KD$--I_B?Q
MQ-?-CYLF+3KJ50B[HV5]I^MO@C_P;U_%?5KNTU+]H'XQ^%O!FEEUFNM`^&UI
M>^,/$4Z%ED-L^M:Q::'HFE7&1(3<V]CXFCW,2(Y,B5?ZT**O"^&'#]*HJN-K
M9CFDE\4,;B(NC/\`Q0I4J<[>4:D5O>X?7JJ^!0I]/<5K[;_UU9\5_LO?\$_O
MV8/V1+*,_"3P!;KXJ:W^SZA\1O$\J>(?'VI(Z;)U?7+N%4TJUN>6N-,\.VFC
M:7*Y,CV1E>1V^U***^]P>"PF7T(8;!8>EAJ$/@I48*$(^B6AR2E*<G*3<I/=
MO=A111742%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
+`%%%%`!1110!_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
